Gain Therapeutics (NASDAQ:GANX) Given New $7.00 Price Target at Maxim Group

Key Points

• Maxim Group has raised its price target for Gain Therapeutics (NASDAQ:GANX) from $5.00 to $7.00, reflecting a potential upside of 251.76% from its previous close.
• Seven analysts currently rate Gain Therapeutics as a "buy," while one analyst issued a "sell" rating, leading to an average rating of "Moderate Buy" and a consensus target price of $7.86.
• Gain Therapeutics reported a loss of ($0.19) earnings per share for the last quarter, missing estimates, and is anticipated to post a total loss of -1 EPS for the current year.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) had its price target lifted by equities researchers at Maxim Group from $5.00 to $7.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Maxim Group's target price indicates a potential upside of 251.76% from the stock's previous close.

A number of other analysts also recently weighed in on the stock. HC Wainwright restated a "buy" rating and issued a $8.00 target price on shares of Gain Therapeutics in a report on Thursday, July 3rd. BTIG Research reissued a "buy" rating and set a $9.00 price objective on shares of Gain Therapeutics in a research note on Monday, September 8th. Roth Capital dropped their target price on Gain Therapeutics from $7.00 to $6.00 and set a "buy" rating for the company in a report on Wednesday, August 13th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Gain Therapeutics in a research note on Saturday, September 27th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $7.86.

Gain Therapeutics Price Performance

GANX stock traded down $0.23 during mid-day trading on Tuesday, hitting $1.99. The company had a trading volume of 1,470,117 shares, compared to its average volume of 349,901. The company has a 50-day moving average price of $1.72 and a 200 day moving average price of $1.78. Gain Therapeutics has a 12-month low of $1.41 and a 12-month high of $3.19. The company has a market capitalization of $71.54 million, a price-to-earnings ratio of -3.20 and a beta of 0.11. The company has a quick ratio of 1.79, a current ratio of 1.79 and a debt-to-equity ratio of 0.09.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.02). On average, research analysts anticipate that Gain Therapeutics will post -1 earnings per share for the current year.

Hedge Funds Weigh In On Gain Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of GANX. Dauntless Investment Group LLC bought a new stake in Gain Therapeutics during the first quarter valued at about $240,000. Marshall Wace LLP raised its holdings in Gain Therapeutics by 41.0% in the second quarter. Marshall Wace LLP now owns 276,433 shares of the company's stock worth $498,000 after purchasing an additional 80,407 shares in the last quarter. Kovitz Investment Group Partners LLC purchased a new stake in shares of Gain Therapeutics during the first quarter valued at about $91,000. Finally, Geode Capital Management LLC raised its stake in shares of Gain Therapeutics by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company's stock worth $523,000 after acquiring an additional 8,251 shares in the last quarter. 11.97% of the stock is currently owned by institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.